Compare ACTG & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACTG | BNTC |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.1M | 396.3M |
| IPO Year | 1995 | 2020 |
| Metric | ACTG | BNTC |
|---|---|---|
| Price | $4.27 | $9.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 167.8K | 124.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,004,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.15 | $9.26 |
| 52 Week High | $5.27 | $16.76 |
| Indicator | ACTG | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 31.22 | 27.48 |
| Support Level | $3.86 | N/A |
| Resistance Level | $4.30 | $13.49 |
| Average True Range (ATR) | 0.11 | 0.74 |
| MACD | -0.03 | -0.24 |
| Stochastic Oscillator | 13.16 | 12.42 |
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations, and Manufacturing Operations. It derives revenue from the Intellectual Property Operations segment. Geographically, it operates in the Americas, Europe, the Middle East and Africa, China, India, and Asia-Pacific.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.